Martinsried/Munich, 27 January 2014. Medigene AG (MDG1, Frankfurt, Prime Standard) has acquired the Munich-based company, Trianta Immunotherapies GmbH (Trianta), a spin-off of the Helmholtz Zentrum München. Trianta is developing three highly innovative and complementary immunotherapy platforms with programs in clinical development to treat various tumour types. Trianta's proprietary technologies will enhance Medigene's advanced pipeline with cutting-edge therapies. Prof. Dolores J. Schendel, Managing Director of Trianta and Director of the Institute for Molecular Immunology at the Helmholtz Zentrum München, is intended to join the Executive Management Board of Medigene as Chief Scientific Officer and will be accompanied by her team of 15 immunotherapy specialists from the Helmholtz Zentrum.
Acquisition structure and financials: Medigene has acquired 100% of Trianta shares. The previous Trianta shareholders will receive 1,017,811 newly issued Medigene shares worth approximately EUR 4 million and potential incremental payments in further Medigene shares or in cash of up to a maximum total of EUR 5.875 million upon the achievement of future milestones. Medigene will partly utilize its authorized capital to issue 1,017,811 new shares which will be subject to a lock-up period of 12 months. This capital measure will increase Medigene's share capital from currently EUR 9,872,139.00 by EUR 1,017,811.00 million to EUR 10,889,950.00 million. Medigene's management continues to anticipate that funding is secured until at least the beginning of 2015. Additional financial and operational guidance will be provided with the annual financial and operations report and conference call on 27 March 2014.
About Trianta: Based on more than 15 years of extensive research in the field of immunotherapy, Trianta Immunotherapies GmbH was founded late 2013 as a spin-off of the Helmholtz Zentrum München, the German Research Centre for Environmental Health. Trianta exploits the therapeutic and commercial potential of T cell-focused therapies developed by the team of Prof. Dolores J. Schendel at the Helmholtz Zentrum München, in collaboration with Prof. Thomas Blankenstein at the Max Delbrück Centre for Molecular Medicine, Berlin. The team of Trianta pursues three complementary immunotherapeutic strategies to target various tumour types and stages. Each one is focused on T cells, a type of white blood cell that plays a pivotal role in immunity. Trianta is developing next generation antigen-tailored dendritic cell (DC) vaccines, T cell receptor (TCR)-based adoptive cell therapy and T cell-targeted antibodies (TABs). Trianta's DC vaccines are being evaluated in two ongoing, externally funded investigator-initiated trials: a clinical phase I/II trial in acute myeloid leukaemia (AML) at the Ludwig-Maximilians University Hospital Großhadern, Munich, and a clinical phase II trial in prostate cancer at the Oslo University Hospital. Trianta's shareholders are DJSMontana Holding GmbH (Munich), BioM AG (Planegg/Martinsried), Prof. Thomas Blankenstein (Berlin) and Ascenion GmbH (Munich).
Further information on the Trianta acquisition is provided with today's press release of Medigene AG at www.medigene.com.
Contact Medigene AG
Julia Hofmann, Claudia Burmester
Tel.: +49 - 89 - 20 00 33 - 33 01, Fax: +49 - 89 - 20 00 33 - 29 20
Raimund Gabriel, +49 89 210 228 30,
The Trout Group
Alan Roemer, +1 646 378 2945